Teriparatide, a bone-building medication typically used for osteoporosis, successfully treated a rare bone tumor called a Brown tumor and healed a pathological hip fracture in a 32-year-old kidney disease patient, according to a 2026 case report. This is the first documented use of teriparatide for a Brown tumor in a large bone, showing significant pain relief and radiographic improvement without requiring surgery.
Researchers reported a breakthrough case where a 32-year-old man with a rare bone tumor called a Brown tumor developed a serious hip fracture. After standard treatments failed, doctors tried a bone-building medication called teriparatide, which is normally used for osteoporosis. The drug worked remarkably well, reducing his pain and helping his bone heal on X-rays. This is the first time doctors have successfully used this medication to treat a Brown tumor in a large bone, offering hope for other patients with this rare condition.
Key Statistics
A 2026 case report published in JBJS Case Connector documented the first successful treatment of a long-bone Brown tumor using teriparatide in a 32-year-old patient with end-stage renal disease and a pathological hip fracture.
The teriparatide-treated patient achieved pain relief and radiographic evidence of bone remodeling and healing, avoiding the need for surgical implant placement despite multiple high-risk factors including kidney disease and complicated fracture patterns.
This case represents a novel application of teriparatide beyond its standard use for osteoporosis, suggesting potential for treating rare bone tumors in patients who cannot safely undergo surgery.
The Quick Take
- What they studied: Whether a bone-building drug called teriparatide could help heal a rare bone tumor and fracture in a patient with severe kidney disease
- Who participated: One 32-year-old man with end-stage kidney disease who developed a rare bone tumor (Brown tumor) and a broken hip bone
- Key finding: Teriparatide successfully reduced pain and promoted bone healing in this patient, as shown by improved X-ray images and clinical improvement
- What it means for you: This case suggests teriparatide might help other patients with rare bone tumors avoid surgery or improve healing after fractures, though more research is needed to confirm this works for others
The Research Details
This is a case report, which means doctors documented the detailed medical story of one patient. The 32-year-old man had end-stage kidney disease (his kidneys no longer worked) and developed a rare bone tumor called a Brown tumor in his hip. Despite taking medications like cinacalcet and vitamin D to control his overactive parathyroid glands, his condition worsened. He eventually needed surgery to remove his parathyroid glands, but this led to a complication called hungry bone syndrome, where his bones became very weak and he broke his hip bone. Instead of doing major surgery to fix the fracture (which was risky because of his kidney disease), doctors decided to try teriparatide, a medication that stimulates bone growth and remodeling.
Case reports are important for identifying new treatment possibilities, especially for rare conditions where large studies are difficult to conduct. Brown tumors are extremely rare, so finding a successful treatment approach in even one patient provides valuable information for doctors treating similar patients. This case is particularly significant because it shows a medication designed for a common bone disease (osteoporosis) may help with a completely different rare bone condition.
As a single case report, this study has important limitations. One patient’s success doesn’t prove the treatment works for everyone with this condition. However, the case is well-documented with imaging evidence (X-rays showing improvement) and clinical improvement (pain relief). The findings are published in a peer-reviewed medical journal, meaning other experts reviewed the work. Readers should understand this is preliminary evidence suggesting a promising direction for future research, not proof that this treatment works for all Brown tumor patients.
What the Results Show
The patient received teriparatide injections to stimulate bone healing after his hip fracture. Over time, he experienced significant pain relief and his X-ray images showed clear improvement in bone healing and remodeling around the Brown tumor site. The bone lesion, which had been growing and causing problems, began to stabilize and improve. This was particularly remarkable because the patient had multiple risk factors that normally make bone healing very difficult: end-stage kidney disease, a complicated fracture pattern, and recent parathyroid surgery. Despite these challenges, the teriparatide treatment appeared to work effectively without requiring major surgery.
The case demonstrated that teriparatide could be safely used in a patient with severe kidney disease, which is important because kidney disease patients often have complicated bone problems. The medication helped avoid the need for surgical implants (like metal plates or artificial joints), which carry higher infection and failure risks in kidney disease patients. The patient’s overall quality of life improved as pain decreased and mobility improved.
According to Gram Research analysis, this appears to be the first documented case of teriparatide successfully treating a Brown tumor in a large bone like the hip. Previous Brown tumor cases have typically been managed with surgery to remove the parathyroid glands or treat the tumor directly. This case suggests a new medical approach that hadn’t been tried before for this rare condition, potentially expanding treatment options for future patients.
This is a single case report involving one patient, so the results cannot be generalized to all Brown tumor patients. The patient’s specific circumstances (young age, particular kidney disease complications, specific fracture type) may not apply to others. Long-term follow-up data beyond what’s reported here would be valuable to confirm lasting benefits. Larger studies with multiple patients would be needed to establish whether teriparatide is truly effective for Brown tumors as a general treatment approach. Additionally, this patient had multiple medical conditions, making it unclear which factors contributed most to the successful outcome.
The Bottom Line
This case suggests teriparatide may be worth considering for Brown tumor patients with fractures, particularly those who cannot safely undergo surgery due to kidney disease or other complications. However, this is based on one patient’s experience. Patients with Brown tumors or similar rare bone conditions should discuss teriparatide with their doctors as a potential option, understanding that more research is needed. Confidence level: Low to Moderate (based on single case evidence, but with promising results).
Patients with Brown tumors, especially those with kidney disease complications, should be aware of this potential treatment option. Doctors treating rare bone tumors and kidney disease patients with bone problems should consider this case when planning treatment. Patients who cannot safely have surgery due to medical complications may particularly benefit from exploring this approach. This is less relevant for people with common bone diseases like typical osteoporosis, which have well-established treatments.
In this case, pain relief began within weeks of starting teriparatide, and X-ray improvements were visible within months. However, bone remodeling is a slow process, and full healing may take many months. Patients considering this treatment should expect gradual improvement rather than immediate results, and should maintain regular follow-up appointments with their doctors to monitor progress.
Frequently Asked Questions
What is a Brown tumor and why is it dangerous?
A Brown tumor is a rare bone lesion caused by severe overactive parathyroid glands. It weakens bones, causing pain and fractures. This 32-year-old patient’s Brown tumor in his hip became so severe it fractured, requiring new treatment approaches since surgery was too risky.
Can teriparatide treat bone tumors?
This 2026 case report shows teriparatide successfully treated one Brown tumor patient’s fracture and pain. However, this is preliminary evidence from a single case. More research is needed to determine if this works for other bone tumor patients or as a standard treatment.
Is teriparatide safe for people with kidney disease?
This case demonstrates teriparatide was safely used in a patient with end-stage kidney disease, showing pain relief and bone improvement. However, kidney disease patients considering this medication should discuss safety with their nephrologist, as individual circumstances vary.
What happens after parathyroid surgery complications?
After parathyroid removal, some patients develop hungry bone syndrome, where bones become very weak and fracture easily. This patient’s hip fracture from hungry bone syndrome was successfully treated with teriparatide instead of risky surgery.
Could this treatment work for my bone condition?
This case involved a very specific rare condition. While promising, one patient’s success doesn’t guarantee results for other bone diseases. Discuss with your doctor whether teriparatide might be appropriate for your specific condition and medical history.
Want to Apply This Research?
- Users with rare bone conditions could track daily pain levels (0-10 scale), mobility improvements (stairs climbed, walking distance), and medication adherence. Weekly photo documentation of swelling or visible changes could complement clinical imaging.
- Set daily reminders for teriparatide injections if prescribed. Log pain levels before and after activity to identify patterns. Track mobility milestones (first time walking without assistance, returning to work, etc.) to visualize progress over weeks and months.
- Maintain a monthly summary of pain trends, mobility improvements, and any side effects. Share this data with healthcare providers before appointments. Track imaging results (X-rays, scans) and clinical assessments over 6-12 months to document bone healing progress and inform ongoing treatment decisions.
This case report describes treatment of one patient with a rare condition and should not be considered medical advice. Brown tumors and end-stage renal disease are serious conditions requiring specialized medical care. Teriparatide is a prescription medication with specific indications and potential side effects. Anyone considering teriparatide or facing similar bone conditions should consult with qualified healthcare providers, including nephrologists and orthopedic specialists, before making treatment decisions. This article summarizes preliminary case evidence and is not a substitute for professional medical evaluation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.